IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

A Review On Adenomyosis: An Updated Causes, Diagnosis And Treatment.

[1]Rithika S, [2]Roopashree S P, [3]Sandhiya P, [4]Swetha T

Department of Pharmacology, Vivekanandha Pharmacy College for Women, Sankari West, Sankari Taluk, Salem District-637303, India.

Vivekanandha Pharmacy College for Women, Veerachipalayam.

Abstract- The gynaecologic disorder known as adenomyosis is heterogeneous. Adenomyosis patients may present with a variety of clinical symptoms. Although patients with adenomyosis can occasionally present asymptomatic, excessive menstrual bleeding and dysmenorrhea are the most prevalent presentations. There are currently no accepted diagnostic imaging standards, making it difficult to determine which course of action is best for each patient. Diagnosing adenomyosis and assessing its response to treatment can be difficult because women with this condition frequently have other related gynaecologic conditions, such as endometriosis or leiomyoma's. This study aimed to present the most recent clinical data concerning the adenomyosis pathophysiology, imaging findings, clinical symptoms, diagnosis, risk factors, and treatment. The idea that adenomyosis arises from endometrial invasion of the myometrium, resulting in changes to the junctional zone, is supported by a number of studies. Imaging tests including magnetic resonance imaging (MRI) and transvaginal ultrasound (TVUS) frequently reveal these alterations. The second most popular explanation holds that pluripotent mullerian fragments that are displaced during embryonic development cause adenomyosis. Historically, adenomyosis was only identified after a hysterectomy; however, research has indicated that biopsies obtained during laparoscopy and hysteroscopy can also identify the condition. A differential diagnosis can be guided by non-invasive imaging. A review is conducted on the most prevalent findings on 2-dimensional/3-dimensional TVUS and MRI. Though new research suggests that 3-dimensional TVUS is preferable to 2-dimensional TVUS for the diagnosis of adenomyosis and may enable the detection of early-stage disease, both two-dimensional TVUS and MRI have reasonable sensitivity and specificity. Adenomyosis treatment options, including both surgical and medicinal ones, are discussed.

Keywords: Adenomyosis, IUDs, Uterine bleeding, Treatment, Endometrium, Uterus wall, Pelvic pain, Dysmenorrhoea, Menstrual cramps, Fibroids.

1. INTRODUCTION

Adenomyosis is a medical disorder defined by the proliferation of endometrial cells, which are atypically situated within myometrial cells of the uterine wall, inside the uterus. This leads to the uterus thickening. Menorrhagia (prolific menses), dysmenorrhea (painful menses), or both are common symptoms in patients with adenomyosis. Additional signs and symptoms include bladder discomfort, persistent pelvic pain, and pain during sexual activity.

Adenomyosis was called endometriosis interna. A non-invasive method of detecting adenomyosis became possible when imaging methods advanced, enabling the disease's early clinical identification. Transvaginal ultrasonography (TVUS) and magnetic resonance imaging (MRI) are increasingly being utilized to detect adenomyosis and plan subsequent therapy because they are said to have comparable sensitivities and specificities in this regard .Patients younger than 39 years old make up 5–25% of cases of adenomyosis, whereas women in their fourth and fifth decades of life account for the bulk of cases. According to recent investigations, endometriosis (65–70% of cases) and leiomyomata (35–55%) are two diseases that co-occur with adenomyosis. Adenomyosis is most commonly associated with multiparity, age above 40, and history of uterine surgery or cesarean delivery. But as of late, the illness has been diagnosed in a growing number of younger infertile women. The information would enable the application of particular protocols in medically assisted reproduction as well as appropriate counseling for these patients. To reduce bias, well-designed studies with verified data are required to determine the best course of action for treating adenomyosis.

2. FIBROIDS

Tumors that develop in a woman's womb (uterus) are called uterine fibroids. Most of the time, these growths are benign (not malignant) and do not progress to malignancy. If fibroids are not developing quickly, bleeding excessively, or causing pain, they might not need to be removed. The majority of fibroids are not treatable. Little fibroid, ranging in length from 1 to 5 cm (pea to cherry size). The size of a medium fibroid ranges from 5 to 10 cm (big orange to plum). Large fibroid: at least 10 cm (grapefruit size and larger)

Options for treatment, should it be necessary, will depend on the symptoms, the type of fibroid it is, and desire to become pregnant in the future.To treat fibroids, hysterectomy is the only option. Fibroids will not return if the uterus is removed entirely, and the symptoms should subside. After a hysterectomy, if the ovaries are left in place, it will not enter menopause. Fibroids can be treated with the medication ulipristal acetate (Esmya). Uterine fibroids can be treated noninvasively with MRI-guided focused ultrasound (FUS), which eliminates the tumors while protecting the healthy uterus.

3. PATHOPHYSIOLOGY

According to the invasion idea, the basal layer of the endometrium serves as a conduit for the invasion of the myometrium by endometrial tissue. In adenomyosis, some of the endometrial tissue may develop and embed into the myometrium rather than being evacuated, contrary to the normal process of endometrial shedding during menstruation. The typical borders between the endometrium and myometrium are disrupted by this invasion.

Metaplastic theory postulates that endometrial-like cells are formed by the metaplasia of myometrial cells. Then, like regular endometrial cells, these altered cells can react to hormonal cues by going through cyclic alterations and bleeding in response to variations in hormone levels.

Developmental Origins: According to some research, adenomyosis may have developed from aberrant cell migration or differentiation during the uterine embryo's embryonic stage.

Hormonal Influence: It is well recognized that estrogen is essential to the pathophysiology of adenomyosis. Endometrial tissue grows and proliferates in response to estrogen. Abnormal estrogen signaling in adenomyosis may cause endometrial tissue to invade the myometrium and grow more rapidly.

Inflammatory Factors: Prolonged uterine inflammation may potentially play a role in the onset and advancement of adenomyosis. The regular architecture of tissues can be upset by inflammation, which also encourages endometrial cells to invade the myometrium.

4. SIGN AND SYMPTOMS

Adenomyosis might occasionally just cause little discomfort or no symptoms at all. But adenomyosis can result in:

Prolonged or intense menstrual bleeding
Severe pelvic pain during menstruation that feels like a knife (dysmenorrhea)
Persistent pelvic discomfort
Painful intercourse (dyspareunia)

5. DIAGNOSIS

Doctors frequently suspect adenomyosis based on your symptoms and the results of one or more of the following tests:

Pelvics exam: Your doctor may find that your uterus has become softer, bigger, or uncomfortable to the touch during a pelvic exam.
Ultrasound: A transvaginal ultrasound creates images of your pelvic organs by using sound waves. There are occasions when these pictures reveal thickening of the uterine wall.
Imaging scans: Uterine enlargement and thickening of specific locations can be seen on magnetic resonance imaging (MRI) scans.
A biopsy may help your doctor rule out more serious conditions. Your doctor takes tissue during a biopsy and looks for indications of more serious illnesses.

6. CHOICE OF DRUGS

The only permanent treatment for adenomyosis is surgical uterine excision. Due to adenomyosis's sensitivity to reproductive hormones, it makes sense that it will diminish after menopause as these hormone levels drop. Adenomyosis can usually be treated for women who are fertile with the objectives being to limit the disease's progression, relieve pain, and lessen heavy menstrual bleeding.

NSAIDs:

Nonsteroidal anti-inflammatory medications, such naproxen and ibuprofen, are frequently used in addition to other forms of treatment to relieve pain. NSAIDs work by reducing cyclooxygenase activity, which prevents the synthesis of prostaglandins. It has been demonstrated that prostaglandins are mainly to blame for dysmenorrhea, or the painful cramping pelvis that comes with menstruation.

LEVONORGESTREL-RELEASING INTRAUTERINE DEVICES:

Adenomyosis can be effectively treated with hormonal IUDs or levonorgestrel-releasing IUDs, like the Mirena. By inducing decidualization of the endometrium and diminishing or stopping menstrual flow, they lessen symptoms. Additionally, hormonal IUDs reduce the endometrial tissue clusters within the

myometrium by aiding in the downregulation of estrogen receptors. This result in less blood flow during the menstrual cycle, improves uterine contraction, and lessens menstrual pain. Hormonal IUDs have been shown in adenomyosis patients to decrease monthly bleeding, enhance iron and anemia levels, lessen discomfort, and even improve adenomyosis with a smaller uterus on imaging tests. Compared to women who have a hysterectomy, patients who can tolerate hormonal IUDs for the treatment of adenomyosis experience comparable symptom relief, improved quality of life, and increased social well-being—at least in the short term. For those who require efficient therapy for their adenomyosis while preserving their possibility for future fertility, hormonal IUDs are especially well-suited. Unusual menstrual flow or spotting is the most frequent adverse side effect of hormonal IUDs.

GnRH AGONIST;

Before beginning ovarian stimulation, each patient got a depot injection of triptorelin acetate, also known as triptorelin, 3.75 mg, intramuscularly every 28 days for at least three months. Based on the patients' age, body mass index (BMI), blood FSH levels, and the quantity of basal antral follicles, the first dosage was established. Triptorelin, a short-acting GnRH agonist, was administered subcutaneously to cause pituitary desensitization 0.05 mg each day till the day of the HCG injection, which was initiated in the mid-luteal phase of the preceding cycle, after 0.1 mg per day for 10 days. The ovarian stimulation method was identical to the one previously mentioned.

ANTIPROGESTOGEN:

The repositioning of mifepristone as a new therapy option for adenomyosis is supported by the fact that it was found to be both safe and effective in treating the condition. Relevance Treatment for adenomyosis, a common chronic gynecological condition, is still lacking. Mifepristone has been used medicinally to treat gynecologic disorders, which has sparked interest in the drug as a possible treatment for adenomyosis. It has been discovered that megepristone may have therapeutic uses in the management of uterine fibroids and endometriosis. According to earlier research, mifepristone therapy prevented mice from developing adenomyosis, reduced uterine volume, raised hemoglobin levels, and suppressed the expression of genes linked to the proliferation, migration, and invasion of primary endometrial cells in adenomyosis by endometrial epithelial cells.

7. CONCLUSION

Even though histology and imaging studies have made strides in defining distinctive characteristics for the diagnosis of adenomyosis, clinical therapy and results are still very uneven. Adenomyosis has been tried to be categorized into clinically meaningful groups, however none of the suggested methods have been implemented. The many methods utilizing histology and imaging criteria are highlighted in this review. Finding viable classification schemes and determining how well they correlate with clinical data is the initial stage. Encouraging the management of this condition, achieving patient treatment goals, and enhancing the quality of life all depend on the unfulfilled need for a classification system that enables doctors to grade the disease and arrange therapies accordingly.

8. REFERENCE

1. Bird C.C., McElin T.W., Manalo-Estrella P. The elusive adenomyosis of the uterus—Revisited. *Am. J. Obstet. Gynecol.* 1972;112:583–593. doi: 10.1016/0002-9378(72)90781-8. [PubMed] [CrossRef] [Google Scholar]

2. Sammour A., Pirwany I., Usubutun A., Arseneau J., Tulandi T. Correlations between extent and spread of adenomyosis and clinical symptoms. *Gynecol. Obstet. Investig.* 2002;54:213–216. doi: 10.1159/000068385. [PubMed] [CrossRef] [Google Scholar]

3. Dueholm M., Lundorf E. Transvaginal ultrasound or MRI for diagnosis of adenomyosis. *Curr. Opin. Obstet. Gynecol.* 2007;19:505–512. doi: 10.1097/GCO.0b013e3282f1bf00. [PubMed] [CrossRef] [Google Scholar]

4. Byun J.Y., Kim S.E., Choi B.G., Ko G.Y., Jung S.E., Choi K.H. Diffuse and focal adenomyosis: MR imaging findings. *Radiographics.* 1999;19:S161–S170. doi: 10.1148/radiographics.19.suppl_1.g99oc03s161. [PubMed] [CrossRef] [Google Scholar]

5. Van den Bosch T., de Bruijn A.M., de Leeuw R.A., Dueholm M., Exacoustos C., Valentin L., Bourne T., Timmerman D., Huirne J.A.F. Sonographic classification and reporting system for diagnosing adenomyosis. *Ultrasound Obstet. Gynecol.* 2019;53:576–582. doi: 10.1002/uog.19096. [PubMed] [CrossRef] [Google Scholar]

6. Gordts S., Brosens J.J., Fusi L., Benagiano G., Brosens I. Uterine adenomyosis: A need for uniform terminology and consensus classification. *Reprod. Biomed. Online.* 2008;17:244–248. doi: 10.1016/S1472-6483(10)60201-5. [PubMed] [CrossRef] [Google Scholar]

7. Kishi Y., Suginami H., Kuramori R., Yabuta M., Suginami R., Taniguchi F. Four subtypes of adenomyosis assessed by magnetic resonance imaging and their specification. *Am. J. Obstet. Gynecol.* 2012;207:114.e111–114.e117. doi: 10.1016/j.ajog.2012.06.027. [PubMed] [CrossRef] [Google Scholar]

8. Kobayashi H., Matsubara S. A Classification Proposal for Adenomyosis Based on Magnetic Resonance Imaging. *Gynecol. Obstet. Investig.* 2020;85:118–126. doi: 10.1159/000505690. [PubMed] [CrossRef] [Google Scholar]

9. Lazzeri L., Morosetti G., Centini G., Monti G., Zupi E., Piccione E., Exacoustos C. A sonographic classification of adenomyosis: Interobserver reproducibility in the evaluation of type and degree of the myometrial involvement. *Fertil. Steril.* 2018;110:1154–1161.e1153. doi: 10.1016/j.fertnstert.2018.06.031. [PubMed] [CrossRef] [Google Scholar]

10. Vercellini P., Viganò P., Somigliana E., Daguati R., Abbiati A., Fedele L. Adenomyosis: Epidemiological factors. *Best Pract. Res. Clin. Obstet. Gynaecol.* 2006;20:465–477. doi: 10.1016/j.bpobgyn.2006.01.017. [PubMed] [CrossRef] [Google Scholar]

11. Nishida M. Relationship between the onset of dysmenorrhea and histologic findings in adenomyosis. *Am. J. Obstet. Gynecol.* 1991;165:229–231. doi: 10.1016/0002-9378(91)90257-R. [PubMed] [CrossRef] [Google Scholar]

12. Levgur M., Abadi M.A., Tucker A. Adenomyosis: Symptoms, Histology, and Pregnancy Terminations. *Obstet. Gynecol.* 2000;95:688–691. doi: 10.1097/00006250-200005000-00011. [PubMed] [CrossRef] [Google Scholar]

13. Rasmussen C.K., Hansen E.S., Dahl S.A.-M., Ernst E., Dueholm M. The effect of transcervical endometrial resection on clinical symptoms related to intrinsic adenomyosis and junctional zone changes. *Eur. J. Obstet. Gynecol. Reprod. Biol. X.* 2019;3:100029. doi: 10.1016/j.eurox.2019.100029. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

14. McCausland A.M. Hysteroscopic myometrial biopsy: Its use in diagnosing adenomyosis and its clinical application. *Am. J. Obstet. Gynecol.* 1992;166:1619–1626. doi: 10.1016/S0002-9378(11)91551-8. discussion 1626–1618. [PubMed] [CrossRef] [Google Scholar]

15. Hulka C.A., Hall D.A., McCarthy K., Simeone J. Sonographic findings in patients with adenomyosis: Can sonography assist in predicting extent of disease? *AJR Am. J. Roentgenol.* 2002;179:379–383. doi: 10.2214/ajr.179.2.1790379. [PubMed] [CrossRef] [Google Scholar]

16. Siegler A.M., Camilien L. Adenomyosis. *J. Reprod. Med.* 1994;39:841–853. [PubMed] [Google Scholar]

17. Molitor J.J. Adenomyosis: A clinical and pathological appraisal. *Am. J. Obstet. Gynecol.* 1971;110:275–284. doi: 10.1016/0002-9378(71)90620-X. [PubMed] [CrossRef] [Google Scholar]

18. Benson R.C., Sneeden V.D. Adenomyosis: A reappraisal of symptomatology. *Am. J. Obstet. Gynecol.* 1958;76:1044–1057; discussion 1057–1061. doi: 10.1016/0002-9378(58)90186-8. [PubMed] [CrossRef] [Google Scholar]

19. Van den Bosch T., Dueholm M., Leone F.P., Valentin L., Rasmussen C.K., Votino A., Van Schoubroeck D., Landolfo C., Installé A.J., Guerriero S., et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: A consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. *Ultrasound Obstet. Gynecol.* 2015;46:284–298. doi: 10.1002/uog.14806. [PubMed] [CrossRef] [Google Scholar]

20. Harmsen M.J., Van den Bosch T., de Leeuw R.A., Dueholm M., Exacoustos C., Valentin L., Hehenkamp W., Groenman F., De Bruyn C., Rasmussen C., et al. Consensus on revised definitions of morphological uterus sonographic assessment (MUSA) features of adenomyosis: Results of a modified Delphi procedure. *Ultrasound Obstet. Gynecol.* 2021;60:118–131. doi: 10.1002/uog.24786. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

21. Exacoustos C., Morosetti G., Conway F., Camilli S., Martire F.G., Lazzeri L., Piccione E., Zupi E. New Sonographic Classification of Adenomyosis: Do Type and Degree of Adenomyosis Correlate to Severity of Symptoms? *J. Minim. Invasive Gynecol.* 2020;27:1308–1315. doi: 10.1016/j.jmig.2019.09.788. [PubMed] [CrossRef] [Google Scholar]

22. Novellas S., Chassang M., Delotte J., Toullalan O., Chevallier A., Bouaziz J., Chevallier P. MRI Characteristics of the Uterine Junctional Zone: From Normal to the Diagnosis of Adenomyosis. *Am. J. Roentgenol.* 2011;196:1206–1213. doi: 10.2214/AJR.10.4877. [PubMed] [CrossRef] [Google Scholar]

23. Liu L., Wong L., Mol B., Condous G., Costa F., Leonardi M. Diagnostic accuracy of transvaginal ultrasound and magnetic resonance imaging for the diagnosis of adenomyosis: Systematic review and meta-analysis. *Ultrasound Med. Biol.* 2019;45:S54. doi: 10.1016/j.ultrasmedbio.2019.07.592. [PubMed] [CrossRef] [Google Scholar]

24. Bazot M., Daraï E. Role of transvaginal sonography and magnetic resonance imaging in the diagnosis of uterine adenomyosis. *Fertil. Steril.* 2018;109:389–397. doi: 10.1016/j.fertnstert.2018.01.024. [PubMed] [CrossRef] [Google Scholar]

25. Grimbizis G.F., Mikos T., Tarlatzis B. Uterus-sparing operative treatment for adenomyosis. *Fertil. Steril.* 2014;101:472–487. doi: 10.1016/j.fertnstert.2013.10.025. [PubMed] [CrossRef] [Google Scholar]

26. Dashottar S., Singh A.K., Debnath J., Muralidharan C.G., Singh R.K., Kumar S. Comparative analysis of changes in MR imaging of pre and post intrauterine progesterone implants in adenomyosis cases. *Med. J. Armed Forces India.* 2015;71:145–151. doi: 10.1016/j.mjafi.2015.01.008. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

27. Chapron C., Tosti C., Marcellin L., Bourdon M., Lafay-Pillet M.C., Millischer A.E., Streuli I., Borghese B., Petraglia F., Santulli P. Relationship between the magnetic resonance imaging appearance of

adenomyosis and endometriosis phenotypes. *Hum. Reprod.* 2017;32:1393–1401. doi: 10.1093/humrep/dex088. [PubMed] [CrossRef] [Google Scholar]

28. Habiba M., Benagiano G. Classifying Adenomyosis: Progress and Challenges. *Int. J. Environ. Res. Public Health.* 2021;18:12386. doi: 10.3390/ijerph182312386. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

29. Celli V., Dolciami M., Ninkova R., Ercolani G., Rizzo S., Porpora M.G., Catalano C., Manganaro L. MRI and Adenomyosis: What Can Radiologists Evaluate? *Int. J. Environ. Res. Public Health.* 2022;19:5840. doi: 10.3390/ijerph19105840. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

30. Raimondo D., Raffone A., Aru A.C., Giorgi M., Giaquinto I., Spagnolo E., Travaglino A., Galatolo F.A., Cimino M., Lenzi J., et al. Application of Deep Learning Model in the Sonographic Diagnosis of Uterine Adenomyosis. *Int. J. Environ. Res. Public Health.* 2023;20:1724. doi: 10.3390/ijerph20031724. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

31. Canis M., Gremeau A.S., Bourdel N. Elusive adenomyosis: A plea for an international classification system to allow artificial intelligence approaches to reset our clinical management. *Fertil. Steril.* 2018;110:1039–1040. doi: 10.1016/j.fertnstert.2018.08.008. [PubMed] [CrossRef] [Google Scholar]

32. Sanaz Ghazal. Healthline. Understanding Adenomyosis, a Uterine Condition. Available from; https://www.healthline.com/health/adenomyosis Accessed on 09/05/2022.

33. Maheshwari, A.; Gurunath, S.; Fatima, F.; Bhattacharya, S. (2012). "Adenomyosis and subfertility: A systematic review of prevalence, diagnosis, treatment and fertility outcomes". Human Reproduction Update 18 (4): 374–392. doi:10.1093/humupd/dms006

34. Brosens, I., et al., Uterine Cystic Adenomyosis: A Disease of Younger Women. J Pediatr Adolesc Gynecol, 2014.

35.Florence Bryd. WebMD. What is Adenomyosis? Available from; https://www.webmd.com/women/guide/adenomyosis-symptoms-causes-treatments. Accessed on 09/05/2022

36.Shrestha, A., et al., Adenomyosis at hysterectomy: prevalence, patient characteristics, clinical profile and histopatholgical findings. Kathmandu Univ Med J (KUMJ), 2012. 10(37): p. 53-6.

37.Lazzeri L, Di Giovanni A, Exacoustos C et al. Preoperative and postoperative clinical and transvaginal ultrasound findings of adenomyosis in patients with deep infiltrating endometriosis. Reprod. Sci. doi:10.1177/1933719114522520 (2014) (Epub ahead of print).

38.Maheshwari, A., et al., Adenomyosis and subfertility: a systematic review of prevalence, diagnosis, treatment and fertility outcomes. Hum Reprod Update, 2012. 18(4): p. 374-92.